Direct-acting antivirals

A policy brief, developed by TAG, presents online survey data from 23 countries on some of the key HCV diagnostics and policy barriers that inhibit access to HCV care in LMICs. More

A policy brief, developed by TAG, presents online survey data from 23 countries on some of the key HCV diagnostics and policy barriers that inhibit access to HCV care in LMICs. More

Ravidasvir is the first HCV cure to be developed through South-South collaboration and with funding and clinical support from non-profit organizations. It is now recommended for use in combination with sofosbuvir as an alternative pangenotypic DAA. More

An article in 2023 issue of TAGline explores how to reimagine HCV elimination strategies now that intellectual property is no longer restricting access to generic cures. More

An article in 2023 issue of TAGline explores how to reimagine HCV elimination strategies now that intellectual property is no longer restricting access to generic cures. More